Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Research Article Volume 6 Issue 1

COVID-19 Severity and Serum Level of Procalcitonin: A Systematic Review

Mohamed Awny Abdelhamid Abouhemda*

Mabarat El Maadi Hospital, El Maadi, Cairo, Egypt

*Corresponding Author: Mohamed Awny Abdelhamid Abouhemda, Mabarat El Maadi Hospital, El Maadi, Cairo, Egypt.

Received: November 29, 2021; Published: December 23, 2021


Objective: To review the serum level of procalcitonin in relation to COVID-19 severity.

Data Sources: All articles published between 2003 and 2021 were subjected to a comprehensive search of MEDLINE (PubMed, Medscape, Science Direct, EMF-Portal) and the Internet.

Study Selection: English-language reports of procalcitonin and COVID-19 were chosen for this study. The initial search yielded 127 articles, 51 of which met the requirements for inclusion.

Data Extraction: Articles that did not include procalcitonin or COVID-19 in the title or abstract were excluded from the study. Data on methodology was collected by 26 independent investigators.

Data Synthesis: Structured reviews were used to make comparisons, with the results tallied. COVID-19 mortality-related risk factors have been studied in 21 studies, while PCT level has been studied in 30 studies in relation to COVID-19 severity.

Findings: As of 2020, Egypt's total number of COVID-19 patients is predicted to be in the range of 710–5241 patients. Dyspnea, diabetes mellitus, lymphopenia, elevated CRP, ESR, ferritin, ALT, AST, low albumin, increased D-dimer, and the presence of CT chest abnormalities might all be used as predictors for COVID-19 severity. Most prior investigations discovered a statistically highly significant relationship between serum procalcitonin levels and COVID-19 severity (p0.001).

Conclusion: Demographic, clinical, haematological, biochemical, and imaging data, as well as dyspnea, diabetes mellitus, obesity, smoking, lymphopenia, elevated CRP, ESR, ferritin, ALT, AST, low albumin, increased D-dimer, and the presence of CT chest findings, were found to be predictors of COVID-19 severity in this study. These aspects should be given extra attention, and more evaluations should be done to look into the underlying processes of these effects. PCT may also serve as a predictor of disease severity and aid in identifying the severity of COVID-19 patients. Serial PCT measurements may also be helpful in predicting prognosis. Additional research is needed to better understand the methods by which more PCT is produced and released in SARSCoV-2 patients.

Keywords: Covid-19; Procalcitonin; Mortality Risk; Egyptian Patients; Severity Disease


  1. Wang D., et al. “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China”. JAMA11 (2020): 1061-1069.
  2. Hu R., et al. “Procalcitonin levels in COVID-19 patients”. International Journal of Antimicrobial Agents2 (2020): 106051.
  3. Liu ZM., et al. “Association of procalcitonin levels with the progression and prognosis of hospitalized patients with COVID-19”. International Journal of Medical Sciences16 (2020): 2468.
  4. Udugama B., et al. “Diagnosing COVID-19: the disease and tools for detection”. ACS Nano 4 (2020): 3822-3835.
  5. Saba AI and Elsheikh AH. “Forecasting the prevalence of COVID-19 outbreak in Egypt using nonlinear autoregressive artificial neural networks”. Process Safety and Environmental Protection 141 (2020): 1-8.
  6. Ruan Q., et al. “Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China”. Intensive Care Medicine5 (2020): 846-848.
  7. Ponti G., et al. “Biomarkers associated with COVID-19 disease progression”. Critical Reviews in Clinical Laboratory Sciences6 (2020): 389-399.
  8. Ticinesi A., et al. “The Clinical Significance of Procalcitonin Elevation in Patients over 75 Years Old Admitted for COVID-19 Pneumonia”. Mediators of Inflammation (2021).
  9. Fajgenbaum DC and June CH. “Cytokine storm”. New England Journal of Medicine23 (2020): 2255-2273.
  10. Li H., et al. “SARS-CoV-2 and viral sepsis: observations and hypotheses”. The Lancet10235 (2020): 1517-1520.
  11. Tjendra Y., et al. “Predicting disease severity and outcome in COVID-19 patients: a review of multiple biomarkers”. Archives Of Pathology and Laboratory Medicine12 (2020): 1465-1474.
  12. Malik P., et al. “Biomarkers and outcomes of COVID-19 hospitalizations: systematic review and meta-analysis”. BMJ Evidence-Based Medicine3 (2021): 107-108.
  13. Guirguis-Blake J., et al. “Current processes of the U.S. Preventive Services Task Force: refining evidence-based recommendation development”. Annals of Internal Medicine 2 (2007): 117-122.
  14. Hassany M., et al. “Estimation of COVID-19 burden in Egypt”. The Lancet Infectious Diseases8 (2020): 896-897.
  15. Hong K-H., et al. “Predictors of mortality in Middle East respiratory syndrome (MERS)”. Thorax3 (2018): 286-289.
  16. Choi KW., et al. “Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong”. Annals of Internal Medicine 9 (2003): 715-723.
  17. Wang K., et al. “Clinical and laboratory predictors of in-hospital mortality in 305 patients with COVID-19: a Cohort Study in Wuhan, China”. China16 (2020): 2079-2088.
  18. Goronzy JJ and Weyand CM. “Successful and maladaptive T cell aging”. Immunity3 (2017): 364-378.
  19. Abate S., et al. “Prevalence and risk factors of mortality among hospitalized patients with COVID-19: a systematic review and Meta-analysis”. Bull World Health Organ (2020).
  20. Alqahtani JS., et al. “Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis”. PLoS ONE5 (2020): e0233147.
  21. Scully EP., et al. “Considering how biological sex impacts immune responses and COVID-19 outcomes”. Nature Reviews Immunology 20 (2020): 442-447.
  22. Abdullah M., et al. “Gender effect on in vitro lymphocyte subset levels of healthy individuals”. Cell Immunology2 (2012): 214-219.
  23. Parohan M., et al. “Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies”. The Aging Male5 (2020): 1416-1424.
  24. Zhou F., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. Lancet 395 (2020): 1054-1062.
  25. Van Gerwen M., et al. “Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study”. Journal of Medical Virology 2 (2021): 907-915.
  26. Soares RdCM., et al. “Risk factors for hospitalization and mortality due to COVID-19 in Espírito Santo State, Brazil”. American Journal of Tropical Medicine and Hygiene 3 (2020): 1184-1190.
  27. Dessie and Zewotir BMC Infectious Disease 21 (2021):
  28. Fang L., et al. “Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?” The Lancet Respiratory Medicine4 (2020): e21.
  29. Ghweil AA., et al. “Characteristics, outcomes and indicators of severity for COVID-19 among sample of ESNA Quarantine Hospital’s Patients, Egypt: a retrospective study”. Infection and Drug Resistance 13 (2020):
  30. Fadini G., et al. “Prevalence and impact of diabetes among people infected with SARS-CoV-2”. Journal of Endocrinology Investigation6 (2020): 867-869.
  31. Wang B., et al. “Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis”. Aging (Albany NY) 7 (2020): 6049.
  32. Alqahtani JS., et al. “Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis”. PLoS ONE 5 (2020): e0233147.
  33. Williams NP., et al. “Impact of radiologically stratified exacerbations: insights into pneumonia aetiology in COPD”. Respiratory Research 1 (2018): 143.
  34. Klang E., et al. “Morbid obesity as an independent risk factor for COVID-19 mortality in hospitalized patients younger than 50”. Obesity 9 (2020): 1595-1599.
  35. Hernández-Galdamez DR., et al. “Increased risk of hospitalization and death in patients with COVID-19 and pre-existing noncommunicable diseases and modifiable risk factors”. Archives of Medical Research7 (2020): 683-689.
  36. Mikami T., et al. “Risk factors for mortality in patients with COVID-19 in New York City”. Journal of General Internal Medicine 36 (2021): 17-26.
  37. Chilimuri S., et al. “Predictors of mortality in adults admitted with COVID-19: retrospective cohort study from New York City”. Western Journal of Emergency Medicine 4 (2020): 779.
  38. Wu C., et al. “Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China”. JAMA Internal Medicine 7 (2020): 934-943.
  39. Shah S., et al. “Elevated D-dimer levels are associated with increased risk of mortality in COVID-19: a systematic review and meta-analysis”. Cardiology in Review 6 (2020): 295-302.
  40. Zhou F., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. The Lancet 395 (2020): 1054-1062.
  41. Bhandari S., et al. “Clinical profile of Covid-19 infected patients admitted in a tertiary care hospital in North India”. Journal Associate of Physicians India 5 (2020): 13-17.
  42. Cecconi M., et al. “Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for Covid-19 infection in Lombardy, Italy”. Journal of Clinical Medicine 5 (2020): 1548.
  43. Cen Y., et al. “Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019 - a multi-centre observational study”. Clinical Microbiology and Infection 9 (2020): 1242-1247.
  44. Chen R., et al. “Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in china”. Chest1 (2020): 97-105.
  45. Chen R., et al. “Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China”. The Journal of Allergy and Clinical Immunology 1 (2020): 89-100.
  46. Chen T., et al. “Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study”.Journals of Gerontology Series A: Biological Sciences and Medical Sciences 9 (2020): 1788-1795.
  47. Chen X., et al. “Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: a retrospective study from a single center”. Journal of Medical Virology 9 (2020): 1572-1579.
  48. Duan J., et al. “Correlation between the variables collected at admission and progression to severe cases during hospitalization among patients with COVID-19 in Chongqing”. Journal of Medical Virology 11 (2020).
  49. Gavin W., et al. “Clinical characteristics, outcomes and prognosticators in adult patients hospitalized with COVID-19”. American Journal of Infection Control 9 (2020): 158-165.
  50. Gregoriano C., et al. “Characteristics, predictors and outcomes among 99 patients hospitalized with COVID-19 in a tertiary care centre in Switzerland: an observational analysis”. Swiss Medical Weekly150 (2020):
  51. Guo T., et al. “Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)”. JAMA Cardiology7 (2020): 811-818.
  52. Hong Y., et al. “Clinical characteristics of coronavirus disease 2019 and development of a prediction model for prolonged hospital length of stay”. Annals of Translational Medicine 7 (2020): 443.
  53. Hou H., et al. “Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19”. Clinical Experimental Immunology1 (2020): 76-84.
  54. Hu R., et al. “Procalcitonin levels in COVID-19 patients”. International Journal of Antimicrobial Agents 2 (2020): 106051.
  55. Ke C., et al. “2019 Novel coronavirus disease (COVID-19) in hemodialysis patients: a report of two cases”. Clinical Biochemistry 81 (2020): 9-12.
  56. Li H., et al. “Serum amyloid A is a biomarker of severe coronavirus disease and poor prognosis”. Journal of Infection 6 (2020): 646-655.
  57. Li R., et al. “Clinical characteristics of 225 patients with COVID-19 in a tertiary hospital near Wuhan, China”. Journal of Clinical Virology 127 (2020):
  58. Lima B., et al. “COVID-19 in recent heart transplant recipients: clinicopathologic features and early outcomes”. Transplant Infectious Disease 5 (2020):
  59. McRae MP., et al. “Clinical decision support tool and rapid point-of-care platform for determining disease severity in patients with COVID-19”. Lab on a Chip 12 (2020): 2075-2085.
  60. Ortiz-Brizuela E., et al. “Clinical and epidemiological characteristics of patients diagnosed with Covid-19 in a tertiary care center in Mexico City: a prospective cohort study”. Revista de Investigación Clínica 3 (2020): 165-177.
  61. Price-Haywood EG., et al. “Hospitalization and mortality among black patients and white patients with Covid-19”. New England Journal of Medicine26 (2020): 2534-2543.
  62. Rastrelli G., et al. “Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients”. Andrology1 (2020): 88-89.
  63. Rath D., et al. “Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection”. Clinical Research Cardiology12 (2020): 1491-1499.
  64. Sattar Y., et al. “Coronavirus disease 2019 with acute respiratory distress syndrome mimicking heart failure exacerbation: time to rethink”. Cardiology Research3 (2020): 196-199.
  65. Shao L., et al. “Novel insights into illness progression and risk profiles for mortality in non-survivors of COVID-19”. Frontiers in Medicine (Lausanne) 7 (2020):
  66. Zaninotto M., et al. “Presepsin in risk stratification of SARS-CoV-2 patients”. Clinica Chimica Acta 507 (2020): 161-163.
  67. Zeng Z., et al. “Simple nomogram based on initial laboratory data for predicting the probability of ICU transfer of COVID-19 patients: multicenter retrospective study”. Journal of Medical Virology (2020).
  68. Zhang B., et al. “Novel coronavirus disease 2019 (COVID-19): relationship between chest CT scores and laboratory parameters”. European Journal of Nuclear Medicine and Molecular Imaging 9 (2020): 2083-2089.
  69. Zhang G., et al. “Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China”. Journal of Clinical Virology 127 (2020):
  70. Zhang J., et al. “Clinical, radiological and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients”. Allergy2 (2020): 533-550.


Citation: Mohamed Awny Abdelhamid Abouhemda. “COVID-19 Severity and Serum Level of Procalcitonin: A Systematic Review”.Acta Scientific Medical Sciences 6.1 (2022): 248-258.


Copyright: © 2022 Mohamed Awny Abdelhamid Abouhemda. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue".
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US